The U.S. Food and Drug Administration Approves Epcoritamab-bysp (Epkinly) for Diffuse Large B-Cell Lymphoma
On May 19, 2023 the U.S. Food and Drug Administration (FDA) announced it has approved…
News
Lymphoma Research Foundation Funds 27 New Grants Supporting the Next Generation of Lymphoma Scientists
Lymphoma Research Foundation Awards More Than $5.4 Million in Lymphoma Research Grants New York, NY…
The U.S. Food and Drug Administration Approves Polatuzumab Vedotin-piiq (Polivy) for Diffuse Large B-Cell Lymphoma
On April 19, 2023 the U.S. Food and Drug Administration (FDA) announced it has approved polatuzumab…
Update on AbbVie Withdrawal of Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications
On April 6, 2023, AbbVie announced its intent to withdraw the accelerated approval of ibrutinib…
Read the Latest Issue of Pulse: Winter 2023
Read the Spring 2022 edition of Pulse. This issue of Pulse introduces our 2022 Clinical Investigator Career Development Award (CDA) and Postdoctoral Fellowship and Follicular
Lymphoma Priority Research Grantees.
The Importance of Being Seen and Heard
The Importance of Being Seen and Heard In April 2021, Paula Ngon was an active,…
Updates from the 2022 American Society of Hematology Annual Meeting
Updates from the 2022 American Society of Hematology Annual Meeting The Lymphoma Research Foundation (LRF)…
ASH 2022: High Rates of Progression-Free Survival and MRD Undetectability in Patients with Chronic Lymphocytic Leukemia Receiving Ibrutinib Plus Venetoclax
ASH 2022: High Rates of Progression-Free Survival and MRD Undetectability in Patients with Chronic Lymphocytic…
ASH 2022: Primary Central Nervous System Lymphoma Survival Improved with Consolidation Therapy
ASH 2022: Primary Central Nervous System Lymphoma Survival Improved with Consolidation Therapy Consolidation with either…
ASH 2022: Addition of Lenalidomide to Rituximab Therapy is Associated with Improved Survival in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
ASH 2022: Addition of Lenalidomide to Rituximab Therapy is Associated with Improved Survival in Relapsed/Refractory…
Stay informed with news, alerts and other resources.
